Scientists have developed a promising new approach to treating Alzheimer’s disease by turning ordinary brain cells into powerful plaque-clearing machines. Instead of requiring frequent antibody ...

Neurodegenerative diseases affect more than 57 million people globally. The incidence of these diseases, from Alzheimer's to Parkinson's to ALS and beyond, is expected to double every 20 years.

GLP-1 drugs like Ozempic and Wegovy aid in weight loss by suppressing appetite. Researchers are looking next at how the body expends energy – including through fat.

Researchers discovered that exposing cancer cells to vibration mimicking vocal cord movement reduced their malignancy.

Neurodegenerative diseases affect more than 57 million people globally. The incidence of these diseases, from Alzheimer's to Parkinson's to ALS and beyond, is expected to double every 20 years. Though ...

Swallowing is a fundamental human function that supports nutrition and communication. Damage to swallowing muscles can reduce quality of life and even lead to aspiration pneumonia or malnutrition.

The researchers explored whether cells collected from inside the mouth could reveal signs of schizophrenia. These cells, known as buccal cells, line the inside of the cheeks and can be collected ...

A simple cheek swab could one day provide a quick and noninvasive diagnostic test for schizophrenia. A new study published in ...

A small colored fish pokes out its head from a coral. An Acanthemblemaria Blenny pokes out its head from a coral in the waters of Panama. Credit: Tim Treuer Food chains in the coral reefs of the ...

Wetlands like South Sudan's Sudd swamp saw more rainfall in 2020 due to the La Niña climate event, which caused more methane to enter the atmosphere. Inna67895 via Wikimedia Commons As the world ...

Real estate agents will tell you that a home’s most important feature is “location, location, location.” It’s similar in neuroscience: “Location is everything in the brain,” said Bosiljka Tasic, a ...

Industry-leading non-human primate (NHP) data validates CREATE's differentiated receptor design, targeted RNA-LNP platform, and ability to repeat dose Clinical entry planned H2 2026 CAMBRIDGE, Mass., ...